Plasminogen activator inhibitor-1 (PAI-1) is present in the platelet ^-granule and is released on platelet activation. Platelet PAI-1 could either be synthesized by the megakaryocyte or taken up from the plasma. In this report we confirm the presence of PAI-1 protein in human megakaryocytes by Western blot analysis and show its synthesis in guinea pig megakaryocytes by metabolic labeling. We document the presence of PAI-1 mRNA in human platelets and show a 3-kb mRNA species on Northern blot analysis of guinea pig megakaryocytes. Neither untreated CHRF-288 cells, a megakaryoyblastic cell line, nor human erythroleukemia ( 
blot analysis of megakaryocyte cell extracts. More recently, Simpson et al 10 reported positive PAI-1 immunostaining of human platelets and megakaryocytes. However, Perez et al 1 ' did not find PAI-1 mRNA on Northern blot analysis of human platelet RNA, nor could they amplify PAI-1-specific cDNA from reverse-transcribed (RT) human platelet RNA, leading them to question whether PAI-1 is synthesized by megakaryocytes.
We now report studies confirming the synthesis of PAI-1 protein by human megakaryocytes and show that human platelets and guinea pig megakaryocytes contain PAI-1 mRNA. We also report that PAI-1 mRNA expression is induced in the megakaryoblastic cell line CHRF-288 by phorbol ester treatment.
Methods

Megakaryocyte Isolation
Guinea pig megakaryocytes were isolated as previously described. 1213 Briefly, bone marrow was obtained from the long bones of animals weighing 300-500 g and separated by density gradient centrifugation and two successive velocity sedimentations on bovine albumin gradients. Megakaryocytes were counted, and contamination was assessed by phase-contrast microscopy. Viability was evaluated by trypan blue exclusion. The isolated cells contained 85% megakaryocytes by cell number and >98% megakaryocytes by cell volume.
Human megakaryocytes were propagated from peripheral blood in liquid culture as previously described. 14 Cultures were initiated in E. Mazur's laboratory, sent to P. Schick's laboratory on day 11, and then incubated for 24 hours before separation by the Celsep procedure. The Celsep procedure, described in detail elsewhere, 13 allows the isolation of subpopulations of megakaryocytes according to size. The largest cells are isolated in fractions 2-6, and there is a progressive decrease in size in subsequent fractions. Since megakaryocytes are larger than other bone marrow cells, they are recovered in fractions 2-18 and nonmegakaryocytic cells are isolated in fractions 19-22. Platelets are not present in any fraction. In the culture before separation by the Celsep procedure, 9.6% of the cells were megakaryocytes. After purification, fractions 2-18 were combined and used for Western blot analysis. Together these fractions contained =55% megakaryocytes. Megakaryocytes were identified by morphology and vWF immunostaining. Trypan blue exclusion revealed that the megakaryocytes were 79% viable.
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated and propagated as previously described. 15 Total cellular RNA was extracted at the third passage. Human erythroleukemia (HEL) cells were obtained from the American Tissue Type Collection (ATTC TIB 180, HEL 92.1.7) and propagated in RPMI 1640 (GIBCO BRL, Gaithersburg, Md.) with 10% fetal bovine serum (Hyclone Labs, Logan, Utah). CHRF-288 cells, kindly provided by M. Lieberman, Children's Hospital Medical Center, Cincinnati, Ohio, were propagated in Fischer's medium (GIBCO BRL) with 20% horse serum (GIBCO BRL). All cultures were maintained in a 5% CO 2 humidified atmosphere at 37°C.
Western Blot Analysis
Megakaryocytes were solubilized in 0.125 M tris(hydroxymethyl)aminomethane hydrochloride (Tris HC1), pH 6.8, 4% sodium dodecyl sulfate (SDS), 20% glycerol, and 10% /3-mercaptoethanol. Approximately 42 fig protein, representing =42,000 megakaryocytes, was subjected to polyacrylamide gel electrophoresis (PAGE) in the presence of SDS on a 5% gel. Proteins were electrophoretically transferred to a nitrocellulose membrane (Bio-Rad, Richmond, Calif.); incubated with a rabbit polyclonal anti-human PAI-1 antibody kindly provided by D. Ginsburg, University of Michigan, Ann Arbor; and developed using a horseradish peroxidase-conjugated goat anti-rabbit IgG (Bio-Rad). Controls using rabbit IgG produced no band.
Immunoprecipitation
Isolated megakaryocytes were incubated with 100 jtiCi/mL of Expre S]cysteine; Dupont NEN, Boston, Mass.) for 17 hours at 37°C. After incubation, cells were disrupted by SDS (0.2%) in the presence of protease inhibitors (4 mM EDTA, 2 mM iodoacetic acid, 2 mM iV-ethylmaleimide, and 4 mM phenylmethylsulfonyl fluoride). Gelatin Sepharose (Sigma Chemical Co., St. Louis, Mo.) was added to the cell lysates for 1.5 hours at room temperature and then removed by centrifugation. The samples were then incubated for 1.5 hours at room temperature with protein A-Sepharose beads (Sigma) that had been preincubated for 30 minutes with the polyclonal anti-PAI-1 antibody used for the Western blot analysis. The beads were washed, placed in treatment buffer (0.625 M Tris HC1, pH 6.8,10% glycerol, and 2% SDS), boiled for 3 minutes, and separated by 10% SDS-PAGE. Protein synthesis was detected by fluorography.
Platelet RNA Isolation and Polymerase Chain Reaction
Platelet-rich plasma was prepared from 40 mL of acid/ citrate/dextrose (ACD)-anticoagulated peripheral blood by centrifugation at lOOg for 10 minutes. Washed platelets were prepared by centrifugation at 2,500g for 10 minutes to form a platelet pellet. The pellet was washed twice with ACD, and total RNA was prepared. Alternatively, the platelet-rich plasma was applied to a Sepharose 2B (Pharmacia LKB Technology, Piscataway, N.J.) column that had been equilibrated with calcium-and magnesium-free Tyrode's buffer (0.137 M NaCl, 3 mM KC1, 0.4 mM NaH 2 PO 4 , 12 mM NaHCO 3 , 14.7 mM Af-2-hydroxyethylpiperazine-W-2-ethanesulfonic acid) containing 0.1% bovine serum albumin, 1617 to which ethylene glycol-bis(/3-aminoethyl etherJ-A^A^TV-tetraacetic acid and EDTA (0.5 mM final concentration of each) had been added. The platelet-containing fractions were collected and centrifuged at 2,500g for 10 minutes, and RNA was prepared from the platelet pellet by solubilization in guanidine HC1 as previously described. 18 The RNA was RT and amplified by the polymerase chain reaction (PCR) as previously described. 19 -20 Briefly, one fifth of the isolated RNA was used as a template with 10 units of avian myeloblastosis virus reverse transcriptase (Seikagaku America, Rockville, Md.) for 1 hour at 41°C in 50 mM Tris HC1, pH 8.3, 50 mM KC1, 8 mM MgCl 2 , 10 mM dithiothreitol, and deoxynucleotide triphosphates at 500 /xM each in a total volume of 50 /xL with 0.06 A 26O unit (number of units at 260-nm absorbance) of oligodeoxythymidine 16 as the primer. Ten microliters of the reverse-transcriptase reaction mixture was adjusted to PCR buffer conditions in a total volume of 50 fiL, with 0.02 A 260 unit of each PCR primer and 5 units of Tag polymerase (Thermits aquaticus DNA polymerase, Perkin-Elmer Cetus, Norwalk, Conn.). PCR was performed for 30 cycles in an automated thermocycler (Perkin-Elmer Cetus) with cycle times of 1 minute at 94°C, 1 minute at 55°C, and 2 minutes at 72 C C. Primers used were prepared as based on published nucleotide sequences and included the following: PAI-1 (335-364, 667-638 21 ); vWF (7,116-7,155, 7,824-7,785 22 ); glycoprotein Iba (331-360, 558-529"); and tPA (1,040-1,080, l,543-l,503 24 ). All primers except those for glycoprotein Iba span an intron to control for amplification of residual DNA.
RNA Isolation and Evaluation
Total cellular RNA was prepared by immediate solubilization of the cell fractions in guanidine HC1 (International Biotechnologies, Inc., New Haven, Conn.) as previously described. 18 Except where noted, 10 ju.g of each sample was electrophoresed under denaturing conditions in a formaldehyde-containing gel and transferred to a nylon membrane (Hybond-N, Amersham, Arlington Heights, 111.) by Northern blotting. The RNA was fixed to the membrane with UV irradiation. The blots were prehybridized in 1 M NaCl, 0.1% SDS, 1.5 mg/mL herring sperm DNA, and 10% dextran for 3 hours at 65°C and then hybridized with the appropriate radiolabeled probe at 65°C for 12-24 hours in the prehybridization solution with the addition of 1.5 mg/mL sonicated herring sperm DNA. Blots were washed to various stringencies, depending on the probe used, in a solution containing 0.1-0.2x saline-sodium citrate with 0.1% SDS, 1 mM EDTA (pH 8), and 10 mM sodium phosphate (pH 6.8) at 55°-65°C and analyzed by autoradiography. Densitometric analyses of the autoradiographs were performed using a Hoefer GS300 scanning densitometer and the GS365W data system (Hoefer Scientific Instruments, San Francisco). Densitometry results for PAI-1 mRNA signals were normalized to scans of the same blot reprobed with the cDNA for phosphoglycerate kinase to control for RNA quantification.
Guinea pig PAI-1 and vWF cDNAs and human PAI-1 21 and phosphoglycerate kinase 25 cDNAs were used as probes. Guinea pig-specific PAI-1 and vWF probes were prepared after human-guinea pig crossspecies hybridization did not produce a signal sufficient for evaluation. The guinea pig PAI-1 probe was prepared using PCR to amplify PAI-1 cDNA from RT guinea pig bone marrow or lung RNA by using primers based on the human sequence (published nucleotide sequence No. 335-364 and 667-638 21 ). The guinea pig vWF probe was amplified from the same RT RNA by using primers based on the human sequence (nucleotides 7,116-7,155 and 7,824-7,785 22 ). These procedures were performed as previously described, except that relaxed annealing conditions were used for the first five cycles of the PCR (1 minute at 94°C, 1 minute at 37°C, a gradual increase over 2 minutes to 72°, and 2 minutes at 72°C), and then standard conditions as above were used for the next 25 cycles. The amplified cDNAs were labeled with [ 32 P]deoxycytidine triphosphate using random-hexamer priming. The identity of the guinea pig PAI-1 and vWF probes was confirmed by their ability to detect the appropriately sized message in guinea pig RNA, by cross-hybridization to the appropriate message species in HUVEC RNA under low-stringency hybridization and washing, and by direct sequencing of the amplified bands using a modification of the dideoxy chain-termination method to sequence double-stranded DNA. 26 The sequence of the amplified guinea pig PAI-1 fragment was approximately 90% homologous to the human sequence.
Results
Western blot analysis of protein from isolated human megakaryocytes with an anti-human polyclonal PAI-1 antibody revealed an immunoreactive band of approximately 45 kD, as shown in Figure 1A . The cellular extract also contained vWF immunoreactivity but was nonreactive with control IgG (data not shown). Although the megakaryocyte fraction was only 55% pure, the remainder of the cells were almost entirely small lymphocytes, and no platelets were present. Peripheral blood lymphocytes do not express PAI-1 10 ; thus, it is likely that the PAI-1 immunoreactivity is from megakaryocyte protein, thereby confirming previously published studies.
To determine whether megakaryocytes synthesize PAI-1, guinea pig megakaryocytes were incubated with [ We evaluated human platelets for the presence of PAI-1 mRNA. Vestigial amounts of mRNA remain in platelets when they are separated from the megakary- ocyte, and analysis of this RNA has been used by a number of investigators to study megakaryocyte-derived mRNAs. 192728 PCR analysis of RT RNA prepared from washed platelets and from HUVECs revealed the presence of PAI-1 cDNA as shown in Figure 2 . We were unable to amplify a tPA-specific cDNA fragment from RT platelet RNA under the same conditions but were able to amplify it from RT HUVEC RNA. Segments of vWF and glycoprotein Iba cDNA, which are synthesized in both megakaryocytes and HUVECs, 15 -22 were amplified from both sources. To eliminate possible white blood cell contamination of the platelet pellet, we also gel-purified the platelets (see "Methods"). Using the PAI-1 specific primers, one appropriately sized band was amplified from this RT RNA. Sequence analysis of this product confirmed its identity as PAI-1.
To document the presence of PAI-1 mRNA in megakaryocytes, we evaluated guinea pig megakaryocyte RNA by Northern blot analysis as shown in Figure 3 . Guinea pig megakaryocytes were used because of the number of cells required as well as the ability to obtain purer fractions. The megakaryocytes used were >85% pure by cell number and >98% pure by RNA or protein content, since megakaryocytes are much larger cells and contain greater amounts of RNA and protein per cell. Using a guinea pig-specific PAI-1 probe (see "Methods"), we identified one =3-kb mRNA species. Nonprimate mammals express only one PAI-1 mRNA species in contrast to the two alternatively processed mRNA species seen in primates. 20 The blot reprobed with radiolabeled guinea pig-specific vWF cDNA revealed one =9-kb mRNA species (Figure 3) . In other experiments, Northern blot analysis of RNA prepared from the isolated bone marrow cells in Celsep fractions 20-24, used as controls because they do not contain identifiable megakaryocytes or platelets, showed no mRNA species for either PAI-1 or vWF (data not shown).
Because of the difficulty in isolating and propagating megakaryocytes, investigators have developed and studied cell lines with megakaryocytic properties. HEL cells, a cell line derived from a patient with erythroleukemia, express numerous megakaryocyte proteins in addition to erythroid proteins, especially when stimulated with dimethyl sulfoxide or phorbol esters. 29 - 30 We could not detect PAI-1 mRNA by Northern blot analysis of total cellular RNA extracted from HEL cells that were either untreated or treated for 4 days with dimethyl sulfoxide (1.25%) or the phorbol ester 12-myristate 13-acetate (160 nM) (data not shown). We also evaluated the megakaryoblastic cell line CHRF-288, which was originally established from a metastatic tumor in an infant with acute megakaryoblastic leukemia. 31 PAI-1 mRNA was not detected in untreated or dimethyl sulfoxide-treated CHRF-288 cells but was detected in cells treated for 4 days with phorbol 12-myristate 13-acetate (160 nM), as shown in Figure 4 . When treated with phorbol 12-myristate 13-acetate, approximately one half of the cells become adherent to the tissue culture plastic. RNA from the adherent and suspension cells was isolated separately, and PAI-1 mRNA was induced in both types of cells. The induction was approximately twofold greater in the adherent cells when the results were corrected for RNA quantification.
Discussion
In this article we show that megakaryocytes synthesize PAI-1 mRNA, thus providing a source of platelet PAI-1. PAI-1 is present in the platelet a-granule at a 300-3,000-fold higher concentration than that found in plasma. In a review of platelet a-granule proteins, George 8 postulated that the mechanism of a-granule acquisition is suggested by the relative concentration of the proteins in platelets and plasma. This analysis also suggests that PAI-1 would be synthesized by the megakaryocyte. We cannot, however, rule out that platelet PAI-1 is also acquired by endocytosis of the plasma protein.
Why we were able to detect PAI-1 mRNA in human platelets and Perez et al 11 were not is unclear. This was perhaps due to increased sensitivity of our assays or to the decay of PAI-1 mRNA in the platelet samples they used. Faint PAI-1 immunoreactivity at levels much less than those found in platelets has been reported in granulocytes. 10 Although we confirmed our platelet RNA results by using gel-filtered platelets, we cannot absolutely rule out the possibility of other cell contamination in the platelet RT PCR. However, since megakaryocytes contain PAI-1 mRNA, it is likely that platelets do also. Fay et al 32 even with a small percentage of active PAI-1, significant inhibition of fibrinolysis could occur in a platelet-rich thrombus.
The role of platelets and PAI-1 in clot lysis has been studied by others. Kunitada and coworkers 35 studied tPAinduced lysis of platelet-rich and platelet-poor thrombi formed in vitro. They found that clot lysis was inhibited in the presence of platelets, but they did not think that this was due to PAI-1. With platelets present, they observed the formation of some tPA-PAI-1 complexes, but most of the added tPA was still in the free, active form. They also used a mutant tPA with decreased binding to PAI-1 and found a similar effect on clot lysis as with wild-type tPA. They found that tPA binding to the clot was decreased in platelet-rich thrombi and attributed the decreased lysis to this phenomenon.
Levi and coworkers, 36 however, reported that a monoclonal antibody to PAI-1 enhanced tPA-induced lysis of platelet-rich thrombi formed in vitro. They also studied the effect of incorporating an anti-PAI-1 antibody into the platelet-rich clot on in vivo thrombolysis and clot extension. They found that spontaneous lysis was enhanced by the presence of the anti-PAI-1 antibody but did not find an effect on tPA-induced lysis. They also found decreased clot extension, as measured by fibrinogen accretion, in the anti-PAI-1-containing clots. These studies suggest that the PAI-1 in the thrombus regulates intrinsic thrombus dissolution but does not influence exogenously induced lysis, perhaps because of the inaccessibility of PAI-1 to the lytic agent or to concentration differences.
The idea that PAI-1 activity is not increased with platelet activation stems from studies comparing plasma versus serum samples. 333 This may not reflect local activity in vivo. Vitronectin, which binds and stabilizes PAI-1 in the active form, is present in the platelet and binds to the platelet surface after activation. 37 ' 38 Platelet PAI-1-vitronectin complexes have been documented. 39 Negatively charged phospholipids are capable of activating PAI-1 and could be a mechanism for increased platelet PAI-1 activity with platelet activation.
40 Active PAI-1 could then bind the vitronectin on the platelet surface, thereby increasing the prothrombotic nature of the platelet aggregate.
tPA protein has been identified in both megakaryocytes and platelets, and tPA activity has been observed in megakaryocytes. 9 ' 41 Cultured human megakaryocytes developed a clear zone of fibrinolysis when placed on fibrin films, and this was completely inhibited by antibodies to tPA. 39 Unlike PAI-1, which is present in the platelet a-granule, tPA is distributed diffusely in the platelet and is not released on platelet activation. 9 No studies have reported PAI-1-tPA complexes within platelets, but one study reported complexes in protein extracted from megakaryocytes. 9 Whether this occurred in vivo or after disruption of the megakaryocytes is not known. We could not detect tPA mRNA in guinea pig megakaryocyte RNA by Northern blot analysis (data not shown) or in RT platelet RNA by PCR. Either tPA is not synthesized by megakaryocytes, or tPA mRNA is present at levels not detected by these methods.
Phorbol ester treatment of HEL and CHRF-288 cells induces a more megakaryocyte-like cell, with hyperploidy and increased megakaryocyte-specific protein expression. 30 -31 ' 42 Because phorbol 12-myristate 13-acetate treatment increases PAI-1 gene transcription in human hepatoma and endothelial cells, 43 -44 a direct effect of phorbol 12-myristate 13-acetate on the PAI-1 gene is a possible reason for PAI-1 induction in the CHRF-288 cells. However, unlike in CHRF-288 cells in which induction occurred after 4 days in culture, in hepatoma and endothelial cells the phorbol 12-myristate 13-acetate-induced increase in PAI-1 is seen early (within 4 hours) and is transient, with PAI-1 mRNA levels returning to baseline levels by 12 hours after treatment. Since the induction of PAI-1 mRNA in CHRF-288 cells correlates timewise with the cells differentiating toward more megakaryocyte-like cells, it is likely that the latter factor is important in PAI-1 induction.
Why phorbol 12-myristate 13-acetate treatment induces PAI-1 expression in CHRF-288 cells and not in HEL cells is unknown. Neither HEL nor CHRF-288 cells are pure megakaryocytic cell lines. HEL cells are triphenotypic, expressing erythroid, macrophage, and megakaryocytic markers. 42 CHRF-288 cells were derived from a solid tumor in an infant with megakaryoblastic leukemia and retain some characteristics of the original tumor by producing basic fibroblast growth factor and transforming growth factor-j3. 29 Inducible PAI-1 expression in CHRF cells could be a characteristic remaining from the solid tumor. Alternatively, if PAI-1 is expressed late in megakaryocyte development, then its inducibility in CHRF-288 cells may reflect a more mature megakaryocytic phenotype in these cells. Phorbol ester treatment of HEL cells for longer than 96 hours or under different conditions might also result in PAI-1 induction.
As we have discussed, platelet PAI-1 is most likely derived from its parent megakaryocyte. A number of factors, including tumor necrosis factor, transforming growth factor-/3, interleukin-1, endotoxin, glucocorticoids, epidermal growth factor, and acidic fibroblast growth factor, have been shown to modulate PAI-1 expression in nonmegakaryocytes. 49 If megakaryocyte PAI-1 expression is also modulated, then exposure of the megakaryocyte to these factors in vivo could alter the fibrinolytic potential of the subsequently produced platelet.
